Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Brepocitinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Priovant Expands Brepocitinib to LPP in Phase 2b/3 Trial
    Priovant Expands Brepocitinib to LPP in Phase 2b/3 Trial

    02 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/02/3267158/34323/en/Priovant-Expands-Brepocitinib-Development-Program-with-New-Phase-2b-3-Trial-in-Lichen-Planopilaris-LPP.html

    GLOBENEWSWIRE
    02 Apr 2026
    Share Share
    Roivant Expands Brepocitinib to LPP; Phase 3 Batoclimab Data
    Roivant Expands Brepocitinib to LPP; Phase 3 Batoclimab Data

    02 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/02/3267157/34323/en/Roivant-Announces-Expansion-of-Brepocitinib-Development-Program-with-New-Phase-2b-3-Trial-in-Lichen-Planopilaris-LPP-and-Phase-3-Study-Results-for-Batoclimab-in-Thyroid-Eye-Disease.html

    GLOBENEWSWIRE
    02 Apr 2026
    Share Share
    NEJM Publishes Ph3 VALOR Data For Brepocitinib
    NEJM Publishes Ph3 VALOR Data For Brepocitinib

    28 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/28/3264202/34323/en/New-England-Journal-of-Medicine-Publishes-Positive-Phase-3-VALOR-Trial-Results-of-Brepocitinib-in-Dermatomyositis.html

    GLOBENEWSWIRE
    28 Mar 2026
    Share Share
    Priovant's Brepocitinib Nda For Dermatomyositis Accepted By FDA
    Priovant's Brepocitinib Nda For Dermatomyositis Accepted By FDA

    03 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/03/3248199/34323/en/Priovant-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Brepocitinib-in-Dermatomyositis.html

    GLOBENEWSWIRE
    03 Mar 2026
    Share Share
    Priovant Reports Positive Phase 2 Data For Brepocitinib
    Priovant Reports Positive Phase 2 Data For Brepocitinib

    06 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/06/3233726/34323/en/Priovant-Announces-Positive-Phase-2-Results-for-Brepocitinib-in-Cutaneous-Sarcoidosis-CS.html

    GLOBENEWSWIRE
    06 Feb 2026
    Share Share
    Priovant Advances Brepocitinib To Phase 3 In Skin Disease Study
    Priovant Advances Brepocitinib To Phase 3 In Skin Disease Study

    06 Feb 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/priovant-plots-path-to-phase-3-as-brepocitinib-clears-mid-stage-skin-disease-study

    BIOSPACE
    06 Feb 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.